Head-to-head · Value Score
CoreAge Rx vs Andrew Meds
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Andrew Meds a 70. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameAndrew Meds
#233 · Grade C · Watch List
Est. first month
$199/mo month-to-month (its own sign-up funnels quote $99/mo and $149 for a four-week supply instead)
Save ~85% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 70 — an est. $99/mo first month, with no teaser step-up baked in. Andrew Meds isn't out of it: Shoppers who will start the sign-up before deciding anything, since the price on the product page and the price in the flow behind it are different numbers.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Andrew Meds |
|---|---|---|
| Value Score | 93 (A+) | 70 (C) |
| Est. first month | $99/mo | $199/mo month-to-month (its own sign-up funnels quote $99/mo and $149 for a four-week supply instead) |
| Save vs brand-name | ~89% | ~85% |
| Semaglutide | $99/mo | $199/mo month-to-month (its own sign-up funnels quote $99/mo and $149 for a four-week supply instead) |
| Tirzepatide | $149/mo | $299/mo month-to-month (no sign-up path reached today offered tirzepatide at all) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | All 50 states and D.C. claimed; the sign-up offers 50 and not D.C. |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Andrew Meds
Compounded semaglutide at $199 a month on the product page, $99 in the sign-up flow that page links to, and $149 for a four-week supply in a third — three live prices on one site, and a tirzepatide page whose sign-up does not sell tirzepatide.
Why it's a deal
- The published ladders carry real totals rather than per-month arithmetic: semaglutide at $549 for three months, $999 for six and $1,788 for twelve, with the per-month equivalents printed beside them, so the commitment can be checked
- Both molecules are priced month-to-month on their product pages at $199 and $299, before any intake and with no account
- The pharmacy class is disclosed on the product pages — a "503(A) compounding pharmacy or 503(B) outsourcing facility" — which is more than most desks state, even though no pharmacy is named
- The prescribing practice is named in the footer of every page, with its own address, phone number and support address, so the clinical side is at least attributable to something
- Two side products are priced on the same open basis, including a topical at $79 a month, and the terms state the cancellation mechanics plainly: cancel in-app or by email, effective at the end of the period, two days before renewal
The fine print
- Three semaglutide prices are live at the same time — $199 a month, $99 a month and $149 for four weeks — and nothing on the site says which one a buyer is charged. On a purchase repeated every month that is the whole decision
- Every start button on the compounded-semaglutide page opens a flow headed "Microdosing Program" selling a smaller dose at $99. The word microdose appears nowhere on the page that links to it, so a shopper can arrive expecting the $199 product and be offered a different one
- The tirzepatide sign-up offers exactly one treatment, and it is semaglutide. Whether tirzepatide can be bought through the current flows at all could not be established
- That flow's own ladder is arithmetically broken: one month $149, three months $145, six months $792, with savings that only reconcile if two of the three are totals. A price table that does not add up is not a price table
- The sign-up promises a "100% Success Guarantee" and a refund if you do not lose weight, while the terms say there are no refunds for partially used subscription periods. The guarantee has no matching clause anywhere in the published policies
- The flow runs a live countdown ("Only 40 discounts left. Yours reserved for 9:59 min", observed dropping), quotes efficacy figures with no source, and carries a review badge whose profile does not exist — checked the same day against a known-good profile that did
- The footer claims all 50 states and D.C. and names D.C. among the places a live visit is required, but the sign-up's own state list offers 50 options and D.C. is not one of them
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Andrew Meds.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.